Variant position: 1297 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1863 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human AKASQEHHLSEETKCSASLF SSQCSELEDLTANTNTQDPFL
Gorilla AKTSQEHHLSEETKCSASLF SSQCSELEDLTANTNTQDPFL
Rhesus macaque AKASQEHHLSEETKCSGSLF SSQCSELEDLTANTNTQDPFL
Chimpanzee AKASQEHHLSEETKCSASLF SSQCSELEDLTANTNTQDPFL
Mouse IEASQEHQFSEDPRCSGSMF SSQHSAAQGSTANANSQDSNF
Rat GEASQEYQFSEDAKCSGSMF SSQHSAALGSPANALSQDPDF
Bovine AKVSQEHHLNEEARCSGSLF SSQCSAMEDLTTNTNTQDPFL
Caenorhabditis elegans -------------------- --------DLNLNTAVKKPVV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 1863 Breast cancer type 1 susceptibility protein
1280 – 1280 Phosphoserine; by ATR; in vitro
64 – 1863 Missing. In isoform 2.
224 – 1365 Missing. In isoform 5.
264 – 1366 Missing. In isoform 3 and isoform 6.
1280 – 1280 S -> A. Reduces in vitro phosphorylation by ATR.
1298 – 1298 S -> A. No effect on in vitro phosphorylation by ATR.
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P.; Voigtlaender T.; Bartram C.R.; Klaes R.;
Hum. Mutat. 22:259-259(2003)
Cited for: VARIANTS BC GLY-61; LYS-71; GLN-866; TYR-888; ILE-1139; GLY-1210 AND PRO-1297; VARIANTS BROVCA1 TYR-835 AND PRO-1786;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.